Sign In
Buy BCRX
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026
BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI
07:00am, Monday, 16'th Jun 2025
—Data across pediatric, adolescent, and adult populations demonstrate sustained reductions in HAE attacks and consistent safety profile—
ORLADEYO® (berotralstat) Approved in Colombia
07:00am, Friday, 13'th Jun 2025
RESEARCH TRIANGLE PARK, N.C., June 13, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the National Institute of Drug and Food Surveillance (INVIMA) in Col
BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries
07:00am, Friday, 06'th Jun 2025
RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland
BioCryst Pharmaceuticals (BCRX) is a Great Momentum Stock: Should You Buy?
01:01pm, Wednesday, 04'th Jun 2025
Does BioCryst Pharmaceuticals (BCRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Best Momentum Stock to Buy for June 4th
11:01am, Wednesday, 04'th Jun 2025
BCRX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 4, 2025.
New Strong Buy Stocks for June 4th
06:56am, Wednesday, 04'th Jun 2025
BCRX, OPRX, BWB, PLMR and RACE have been added to the Zacks Rank #1 (Strong Buy) List on June 4, 2025.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Tuesday, 03'rd Jun 2025
RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted s
BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology
07:00am, Monday, 02'nd Jun 2025
RESEARCH TRIANGLE PARK, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the prophy
BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages
07:00am, Friday, 30'th May 2025
New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supports berotralstat use at all stages of life New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supp
BioCryst to Present at Upcoming Investor Conferences
07:00am, Tuesday, 27'th May 2025
RESEARCH TRIANGLE PARK, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade
11:01am, Monday, 26'th May 2025
The mean of analysts' price targets for BioCryst (BCRX) points to a 55.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
RESEARCH TRIANGLE PARK, N.C., May 16, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotra
–FDA grants Priority Review of application, with PDUFA target action date of September 12, 2025– – ORLADEYO would be the first targeted oral prophylactic therapy for patients with HAE under the
Best Momentum Stocks to Buy for May 9th
11:00am, Friday, 09'th May 2025
BCRX, WYY and RMBS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 9, 2025.
New Strong Buy Stocks for May 9th
08:10am, Friday, 09'th May 2025
CBNA, FMS, BNTGY, WYY and BCRX have been added to the Zacks Rank #1 (Strong Buy) List on May 9, 2025.
